Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPV vs Ziv-Aflibercept for Treatment-Naïve DME
NCT03660345Phase 3Completed
- Sponsor
- Rush Eye Associates
- Start
- Sep 2018
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms), sponsored by Rush Eye Associates. Primary endpoint: Best Corrected Visual Acuity at 6 months. Started Sep 2018; status: completed.
Beyond the preview
Go deeper on NCT03660345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660345.